Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 8Gastrointestinal 3Tumor-Agnostic 2CNS 2Sarcoma 1Myeloid 1

Conditions

Glioma 2Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × ivosidenib × CNS × Clear all
NCT02073994 2026-02-17

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Servier

Phase 1 Completed
174 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

NCT03343197 2026-02-17

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Servier

Phase 1 Completed
49 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡